MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) AND VENOUS THROMBOEMBOLISM (VTE) ACROSS UPADACITINIB CLINICAL TRIAL PROGRAMS IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS

被引：0

作者：

Mysler, Eduardo ^{[1
]}

Charles-Schoeman, Christina ^{[2
]}

Choy, Ernest ^{[3
]}

McInnes, Iain ^{[4
]}

Nash, Peter ^{[5
]}

Yamaoka, Kunihiro ^{[6
]}

Lippe, Ralph ^{[7
]}

Khan, Nasser ^{[8
]}

Shmagel, Anna ^{[8
]}

Palac, Hannah ^{[8
]}

Suboticki, Jessica ^{[8
]}

Curtis, Jeffrey ^{[9
]}

机构：

[1] OMI Med Res Org, Buenos Aires, DF, Argentina

[2] Univ Calif Los Angeles, Los Angeles, CA USA

[3] Cardiff Univ, Div Infect & Immun, Cardiff, Wales

[4] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland

[5] Griffith Univ, Brisbane, Qld, Australia

[6] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan

[7] AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany

[8] AbbVie, N Chicago, IL USA

[9] Univ Alabama Birmingham, Birmingham, AL USA

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2023年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PANLAR2023

引用

页码：S75 / S76

页数：2

共 50 条

[31] Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
Peluso, Rosario
Caso, Francesco
Tasso, Marco
Ambrosino, Pasquale
Di Minno, Matteo Nicola Dario
Lupoli, Roberta
Criscuolo, Livio
Caso, Paolo
Ursini, Francesco
Del Puente, Antonio
Scarpa, Raffaele
Costa, Luisa
REVIEWS ON RECENT CLINICAL TRIALS, 2018, 13 (03) : 199 - 209
[32] Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis
Mal, Kheraj
Kumar, Ratan
Mansoor, Farah
Kaur, Navneet
Kumar, Anil
Memon, Sidra
Rizwan, Amber
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)
[33] INTEGRATED SAFETY DATA ANALYSIS ACROSS PHASE 3 CLINICAL STUDIES FOR INTRAVENOUS GOLIMUMAB IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS
Husni, M. E.
Schwartzman, S.
Deodhar, A.
Kafka, S.
Chakravarty, S. D.
Hsia, E. C.
Harrison, D. D.
Leu, J. H.
Zhou, Y.
Lo, K. H.
Kavanaugh, A.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 608 - 609
[34] Impact of biologic therapies on risk of adverse cardiovascular events in patients with Ankylosing Spondylitis or Psoriatic Arthritis: a systematic literature review
Magiouf, K. S.
Fragiadaki, K.
Charpidou, A.
Syrigos, A.
Kotteas, E.
Kourlaba, G.
ARP RHEUMATOLOGY, 2023, 2 (01): : 53 - 63
[35] Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)
Dotan, Arad
Ben-Shabbat, Niv
Watad, Abdulla
McGonagle, Dennis
Amital, Howard
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 969 - 971
[36] Rates of Cardiovascular Disease and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients Compared to Non-Psoriatic Arthritis Patients
Li, Lin
Hagberg, Katrina W.
Peng, Michael M.
Jick, Susan
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 448 - 448
[37] CRANIOMANDIBULAR DISORDERS IN RHEUMATOID-ARTHRITIS, PSORIATIC-ARTHRITIS, AND ANKYLOSING-SPONDYLITIS - A CLINICAL-STUDY
KONONEN, M
WENNEBERG, B
KALLENBERG, A
ACTA ODONTOLOGICA SCANDINAVICA, 1992, 50 (05) : 281 - 287
[38] Rates of serious infectious events and opportunistic infections in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with etanercept or placebo in clinical trials
Hamza, S.
Chon, Y.
Hooper, M.
MacPeek, D.
Lin, S.
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 171 - 172
[39] RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR (CV) EVENTS (MACE) IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH TOCILIZUMAB (TCZ)
Rao, V. U.
Pavlov, A.
Klearman, M.
Musselman, D.
Giles, J. T.
Bathon, J. M.
Sattar, N.
Lee, J. S.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 356 - 357
[40] CLINICAL-TRIAL WITH SULINDAC IN RHEUMATOID-ARTHRITIS AND ANKYLOSING-SPONDYLITIS
MESSIAS, AR
WOLFF, AMM
KRUSE, JL
REVISTA BRASILEIRA DE MEDICINA, 1977, 34 (01) : 35 - 39

← 1 2 3 4 5 →